Achilles Therapeutics has raised more than $175m in its initial public offering on the Nasdaq Global Select Market.

Achilles Therapeutics, a UK-based cancer immunotherapy developer spun out from University College London and Francis Crick Institute, has gone public following an initial public offering that raised more than $175m. The spinout issued 9.75 million American Depositary Shares (ADSs) – representing the same number of ordinary stock – priced at $18 and listed on the…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.